Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

33.26USD
24 Nov 2017
Change (% chg)

$0.39 (+1.19%)
Prev Close
$32.87
Open
$32.89
Day's High
$33.29
Day's Low
$32.52
Volume
112,075
Avg. Vol
351,782
52-wk High
$37.30
52-wk Low
$15.15

Chart for

About

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $2,275.95
Shares Outstanding(Mil.): 69.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.43 15.54
EPS (TTM): -- -- --
ROI: -- 9.96 11.80
ROE: -- 15.21 15.75

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results

Nov 07 2017

BRIEF-Myriad announces GeneSight Psychotropic results from a large prospective trial in patients with major depressive disorder

* Myriad announces GeneSight® Psychotropic results from a large prospective trial in patients with major depressive disorder

Nov 02 2017

BRIEF-‍Myriad Genetics announces new positive results for EndoPredict

* Endopredict (epclin) shown in second study to be more effective than oncotype dx® (rs) in women with intermediate risk of breast cancer recurrence

Oct 26 2017

BRIEF-Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan

* Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer

Oct 24 2017

BRIEF-Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review

* Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer

Oct 18 2017

BRIEF-Myriad Genetics Inc announces launch of riskScore

* Myriad Genetics Inc - September 5, co announced it has launched riskScore - SEC filing Source text: (http://bit.ly/2eDj2Kj) Further company coverage:

Sep 05 2017

BRIEF-EndoPredict receives positive coverage decisions from Medicare and Anthem

* EndoPredict receives positive coverage decisions from Medicare and Anthem

Aug 17 2017

BRIEF-Myriad Genetics Q4 adjusted earnings per share $0.30

* Myriad Genetics reports fiscal fourth-quarter 2017 and fiscal full-year 2017 financial results

Aug 08 2017

BRIEF-Agena Bioscience announces expanded partnership with Assurex Health

* Agena bioscience - assurex health, subsidiary of myriad genetics, has selected massarray system for streamlined laboratory set-up, sample processing of assurex health's genesight test

Jun 20 2017

BRIEF-Myriad Genetics announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

* Myriad Genetics Inc announces results from a large 2,000 patient clinical utility study of its myRisk Hereditary Cancer Test

Jun 02 2017

Competitors

Earnings vs. Estimates